This author has yet to write their bio.Meanwhile lets just say that we are proud Andrew Humphreys contributed a whooping 2904 entries.
With a $26 billion nationwide settlement in sight over claims that the three largest U.S. drug distributors and Johnson & Johnson helped fuel a nationwide opioid epidemic, state and local governments will soon turn their attention to pharmacies and a handful of drugmakers.
Life expectancy in the United States fell by a year and a half in 2020 to 77.3 years – the lowest level since 2003 – primarily due to the deaths caused by the Covid-19 pandemic, a U.S. health agency said on July 21.
Amylyx Pharmaceuticals announced an infusion of $135 million in Series C funds to support the late-stage development of the Boston-based company’s lead candidate, AMX0035, for amyotrophic lateral sclerosis (ALS).
The U.S. Food and Drug Administration sent a letter to Ardelyx Inc. citing “deficiencies” found in the company’s evaluation of the biopharmaceutical firm’s new drug to treat chronic kidney disease (CKD).
The U.S. Food and Drug Administration granted approval to Octapharma USA for Octagam 10% [Immune Globulin Intravenous (Human)], the first intravenous immunoglobulin to be indicated for the treatment of adult dermatomyositis, a rare immune-mediated inflammatory disease.
The three largest U.S. drug distributors agreed mid-trial to pay up to $1.18 billion to settle claims by New York state and two of its biggest counties over their role in the nationwide opioid epidemic, the state’s attorney general said on July 20.
Scientists are working on a benchmark for Covid-19 vaccine efficacy that would allow drugmakers to conduct smaller, speedier human trials to get them to market and address a huge global vaccine shortage.
Swiftly rising coronavirus cases across the United States and abroad fueled fears of a pandemic resurgence on July 19 and sent shockwaves through stock markets as the highly contagious Delta variant appeared to be taking hold.
The U.S. Food and Drug Administration approved Rezurock (belumosudil) as a new treatment option for anyone over 12 years of age with chronic graft-versus-host disease after two prior lines of therapy have failed.
In a roundup of scientific studies on the novel coronavirus, a small study suggests no traces of mRNA vaccines end up in mothers’ breast milk and a gene called IFI27 that becomes activated early in Covid-19 might help identify people most likely to have contracted the virus after coming in contact with an infected person.
